Company profile: Nuvig Therapeutics
1.1 - Company Overview
Company description
- Provider of therapies that induce natural mechanisms to restore immune homeostasis, including NVG-2089, a recombinant, non-immunosuppressive immunomodulator targeting type II Fc receptors to reduce autoimmune dysregulation, in clinical development for inflammatory myopathies and dermatologic autoimmune diseases; recombinant proteins activating immune regulatory receptors; and engineered therapeutic antibodies for autoimmune diseases.
Products and services
- NVG-2089: A recombinant, non-immunosuppressive immunomodulator that targets type II Fc receptors to reduce autoimmune dysregulation, in clinical development for inflammatory myopathies and severe dermatologic autoimmune diseases
- Therapeutic Antibodies: Engineered full-length antibodies constructed to control aggressive autoimmune diseases by maximizing their ability to modulate immune function
- Recombinant Protein: A recombinant protein that selectively activates immune regulatory receptors to rebalance immune function after inflammation, intended for treating chronic autoimmune diseases
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Nuvig Therapeutics
Aditxt
HQ: United States
Website
- Description: Provider of biotechnology solutions using novel nucleic acid-based technologies, including AditxtScore for personalized immune profiling; Apoptotic DNA Immunotherapy (ADI) to induce immune tolerance for transplants, autoimmune diseases, and allergies; Adimune for restoring immune tolerance; Pearsanta for personalized diagnostic and monitoring services; and Adivir developing medicines, diagnostics, and vaccines for public health threats.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Aditxt company profile →
Equillium
HQ: United States
Website
- Description: Provider of therapeutics for autoimmune and inflammatory disorders, including itolizumab, a clinical-stage monoclonal antibody targeting the CD6-ALCAM pathway; EQ101, a tri-specific cytokine inhibitor of IL-2/IL-9/IL-15 in Phase 2 for alopecia areata; EQ302, an oral bi-specific inhibitor of IL-15/IL-21 in pre-clinical; and a multi-cytokine platform generating composite peptides to selectively block key cytokines at shared receptors.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Equillium company profile →
Alpine Immune Sciences
HQ: United States
Website
- Description: Provider of protein-based immunotherapies for autoimmune and inflammatory diseases, using a proprietary directed evolution platform to engineer native immune proteins into multi-targeted therapeutics. Pipeline includes povetacicept (ALPN-303), a dual BAFF/APRIL antagonist, and acazicolcept (ALPN-101), a dual CD28/ICOS antagonist; conducts clinical trials on investigational therapies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Alpine Immune Sciences company profile →
Attralus
HQ: United States
Website
- Description: Provider of biopharmaceutical therapies and imaging agents targeting amyloid and misfolded protein aggregates, including AT-02, a humanized IgG1 antibody fused with a pan-amyloid peptide to stimulate immune removal; AT-01 PET/CT and AT-05 SPECT agents for detecting amyloid deposits; AT-06 preclinical CAR-monocyte therapy; and a neurodegeneration program targeting Aβ, Tau, and α-Synuclein.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Attralus company profile →
VYNE Therapeutics
HQ: United States
Website
- Description: Provider of late-stage biopharmaceutical therapies for dermatologic and immuno-inflammatory diseases via the InhiBET BET Inhibitor Platform. Offerings include VYN201, a locally administered pan-BD BET inhibitor for vitiligo and other diseases with a soft drug approach, and VYN202, an oral BD2-selective BET inhibitor for moderate-to-severe plaque psoriasis and rheumatoid arthritis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full VYNE Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Nuvig Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Nuvig Therapeutics
2.2 - Growth funds investing in similar companies to Nuvig Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Nuvig Therapeutics
4.2 - Public trading comparable groups for Nuvig Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →